© Reuters. Vial, sryinge and small toy figures are seen in front of displayed U.S. flag
By John Miller
ZURICH (Reuters) – Scientists who normally focus on fixing defective genes said on Friday that up to $2.1 million from the Bill & Melinda Gates Foundation will help them move their COVID-19 vaccine candidate toward 2021 human trials.
Harvard University scientist Luk Vandenberghe and University of Pennsylvania gene therapy head James Wilson said primate safety and efficacy tests have proven promising for their single-dose candidate, targeted for room-temperature storage.
“We believe there is real potential,” Vandenberghe said in an interview. “That being said, we’re not naive. There’s 300 vaccines racing towards the door and biology is complex.”
Their candidate relies on an adeno-associated virus (AAV), deemed harmless to humans, to deliver DNA fragments from the new coronavirus, telling human cells to make a protein that provokes an immune response.
AAVs are already used in gene therapies sold by Novartis, including its $2.1 million-per-patient Zolgensma for spinal muscular atrophy. The Swiss company’s gene therapy unit is backing the project with technical assistance and supply.
Other COVID-19 vaccines use viral vectors, too, though AstraZeneca (NASDAQ:) and Oxford University’s shot, Russia’s Sputnik V and Johnson & Johnson (NYSE:)’s one-dose candidate rely on so-called adenoviruses to transport coronavirus DNA.
Gates Foundation money will support more pre-clinical tests ahead of a overseas safety trial in a still-undisclosed location where vaccines are not broadly available, Vandenberghe, who runs Mass General Brigham hospital’s Grousbeck Gene Therapy Center in Boston, said.
Though previously unused in approved vaccines, he is optimistic AAVs will be safe, since only tiny amounts are needed compared to what is required for gene therapies that have been given to many patients.
While he predicts every approved COVID-19 vaccine dose available through 2022 will see use, Vandenberghe acknowledged his group’s success also hinges on finding a deep-pocketed partner with vaccine experience to bankroll large-scale production.
“We’ve already invested more than $10 million,” he said. “If indeed we want to meet the time lines we were just talking about, this needs a commercial larger vaccine player to be accelerated, like an AstraZeneca for Oxford’s.”
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.